Publications by authors named "Cheng-Wan Zheng"
Impact of oxaliplatin and trastuzumab combination therapy on tumor markers and T lymphocyte subsets for advanced gastric cancer.
World J Gastrointest Oncol
September 2024
Article Synopsis
- Advanced gastric cancer (AGC) has a poor prognosis, but combining oxaliplatin and trastuzumab shows potential for improving treatment outcomes by targeting both tumor markers and T lymphocyte subsets.
- In a study with 60 AGC patients, the combination therapy led to significant reductions in serum tumor markers (CEA, CA19-9, CA72-4) and increased levels of CD3+ and CD4+ T lymphocytes after six treatment cycles.
- Patients demonstrating a substantial decrease in tumor markers and an increase in the CD4+/CD8+ T cell ratio had better clinical responses, indicating the potential of these factors as predictive biomarkers for treatment efficacy.